Techcyte
Founded Year
2013Stage
Series C | AliveTotal Raised
$34.62MLast Raised
$8.4M | 2 yrs agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-23 points in the past 30 days
About Techcyte
Techcyte focuses on aiding in the practice of pathology with its artificial intelligence (AI) software platform in the clinical pathology sector. It offers a range of AI-assisted diagnostic tools that improve the efficiency and accuracy of laboratory testing. Techcyte's solutions cater to various applications, including oncology, microbiology, hematology, and infectious disease, as well as industries such as veterinary, environmental, and human healthcare. It was founded in 2013 and is based in Orem, Utah.
Loading...
ESPs containing Techcyte
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology for general diagnostics market refers to the use of digital imaging technology and computational tools to analyze and interpret pathology specimens for diagnostic purposes. Instead of using traditional glass slides, digital pathology involves digitizing tissue samples and creating high-resolution images that can be viewed and analyzed on computer screens. These digital images…
Techcyte named as Outperformer among 15 other companies, including Philips, Proscia, and Ibex.
Techcyte's Products & Differentiators
Techcyte Fusion CP
SAAS-based AI and workflow platform for diagnosing clinical pathology samples. Solution suites for cervical cytology, hematology, parasitology, and bacteriology are available on the platform.
Loading...
Research containing Techcyte
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Techcyte in 3 CB Insights research briefs, most recently on Jul 15, 2024.
Aug 10, 2023
The oncology tech market map
Expert Collections containing Techcyte
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Techcyte is included in 3 Expert Collections, including Digital Health.
Digital Health
11,438 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
568 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Artificial Intelligence
10,195 items
Techcyte Patents
Techcyte has filed 10 patents.
The 3 most popular patent topics include:
- hematology
- immunologic tests
- microscopy
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/17/2020 | 5/28/2024 | Microscopy, Microscopes, Cell imaging, Mass spectrometry, Staining | Grant |
Application Date | 1/17/2020 |
|---|---|
Grant Date | 5/28/2024 |
Title | |
Related Topics | Microscopy, Microscopes, Cell imaging, Mass spectrometry, Staining |
Status | Grant |
Latest Techcyte News
Aug 27, 2025
닫기 [팜뉴스=김응민 기자] AI 기반 디지털 병리 전문 기업 전문기업 딥바이오(대표 김선우)가 테크사이트(Techcyte)와 전략적 파트너십을 체결하고, 딥바이오의 전립선암 진단 및 동결절편 검사 보조 알고리즘을 테크사이트의 Fusion® 플랫폼(유럽 CE 인증 및 미국 RUO )에 통합한다고 오늘 발표했다. 이번 협력은 동결절편 조직병리 진단을 위해 특별히 개발된 AI 알고리즘이 디지털 병리 플랫폼에 통합되는 최초의 사례 중 하나로 기록될 예정이다. 이와 더불어 딥바이오는 유방, 감시 림프절, 폐 동결절편에 대한 AI 알고리즘을 상용화하여 제공하고 있다. 이 동결절편 알고리즘은 종양 검출 및 전이 평가를 지원하도록 설계되었다. 이번 파트너십을 통해 딥바이오는 전립선 및 동결절편 알고리즘을 테크사이트의 클라우드 기반 통합 디지털 병리 플랫폼인 Fusion에 통합하여 연구용으로 고도화된 AI 기능을 제공할 예정이다. 테크사이트 Fusion®은 전체 슬라이드 영상, LIS(병원정보시스템), 환자 데이터, AI 진단 및 협업 도구를 하나의 브라우저 기반 플랫폼으로 통합한다. 딥바이오 김선우 대표는 “DeepDx Prostate은 전립선암 진단의 정확성과 효율성을 높이는 데 중추적인 역할을 한다”며, “이번 파트너십을 통해 Fusion 플랫폼을 통해 전립선 AI 솔루션에 대한 접근성을 확대하고, 병원 및 연구소에 보다 정확하고 실시간적인 의사 결정을 지원하는 도구를 제공할 수 있게 되었다. AI 기반 진단을 전 세계적으로 발전시키려는 우리의 지속적인 사명의 일환으로 테크사이트와 협력하게 되어 기쁘다”고 밝혔다. 테크사이트의 벤 카훈(Ben Cahoon) CEO는 “딥바이오의 DeepDx Prostate AI 기능을 통합하는 것은 Fusion 비전의 자연스러운 연장선이다”며, “딥바이오의 고급 알고리즘과 우리의 디지털 워크플로우를 결합함으로써 병리학 분야에서 AI의 잠재력을 발현하는 데 기여하고 있다”고 말했다. 초기 통합은 딥바이오의 DeepDx Prostate 모델부터 시작되며, 추가 모듈과 동결절편 알고리즘은 향후 Fusion 플랫폼에서 출시될 예정이다. 이러한 통합은 초기에는 연구용(RUO)으로만 제공되며, CLIA 인증 연구소와의 협력을 통해 자체 검증된 워크플로우를 개발하여 향후 채택을 지원할 예정이다. 전반적인 상용화는 규제 경로, 고객 채택 및 지속적인 개발에 따라 진행될 예정이다. 이번 파트너십을 통해 딥바이오는 글로벌 입지를 지속적으로 확대하고 복잡하고 실제적인 병리학적 문제에 대한 AI 솔루션을 제공하는 선도 주자임을 입증하게 되었다.
Techcyte Frequently Asked Questions (FAQ)
When was Techcyte founded?
Techcyte was founded in 2013.
Where is Techcyte's headquarters?
Techcyte's headquarters is located at 1106 North 1200 West, Orem.
What is Techcyte's latest funding round?
Techcyte's latest funding round is Series C.
How much did Techcyte raise?
Techcyte raised a total of $34.62M.
Who are the investors of Techcyte?
Investors of Techcyte include Alta Ventures Mexico, Zoetis, ARUP Laboratories, Paycheck Protection Program, University of Utah and 3 more.
Who are Techcyte's competitors?
Competitors of Techcyte include Proscia and 4 more.
What products does Techcyte offer?
Techcyte's products include Techcyte Fusion CP and 4 more.
Loading...
Compare Techcyte to Competitors
4D Path is a company that operates within the healthcare industry. They have developed a platform that measures and quantifies cell cycle deregulations and tumor microenvironment dynamics to predict patient responses to cancer therapies. Their technology provides biomarker profiling and stratification from histopathology images. It was founded in 2016 and is based in Newton Center, Massachusetts.
Mechanomind provides AI diagnostics for skin cancer within the healthcare technology sector. The company utilizes computer vision and deep learning to assist in the diagnosis of skin cancer, including the classification of skin tumor subtypes and offering decision support for pathologists. Mechanomind's technology is scanner and image quality agnostic, aimed at maintaining accuracy and efficiency in histopathology analysis. It was founded in 2015 and is based in New York, New York.
TRIBVN Healthcare is a company that provides digital pathology solutions, using artificial intelligence to assist in cancer diagnosis within the healthcare sector. The company has a digital pathology platform that includes image management, AI applications for diagnostics, case sharing, and data archiving solutions, aimed at improving the workflow of pathologists. TRIBVN Healthcare serves diagnostic laboratories and pharmaceutical and biotech companies. It was founded in 2011 and is based in Paris, France.
Qritive is a company that focuses on AI diagnostics in the healthcare sector, particularly in pathology. They develop AI solutions to assist pathologists in managing workflows from diagnosis to treatment. Their main offerings include a clinical-decision support system for pathologists and an image management platform called Pantheon, which are intended to support cancer diagnoses. It was founded in 2017 and is based in Singapore, Singapore.
Cerba HealthCare provides medical diagnostics within the healthcare sector. It offers diagnostic services including proximity biology, specialty biology, clinical trial biology, anatomical and cytological pathology, medical imaging, and preventive biology. These services are used for the diagnosis and management of diseases. It was founded in 1967 and is based in Issy-les-Moulineaux, France.
Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.
Loading...